Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 94kWORD 16k
30 June 2017
Question for written answer E-004380-17
to the Commission
Rule 130
Claudiu Ciprian Tănăsescu (S&D) , Ioan Mircea Paşcu (S&D) , Viorica Dăncilă (S&D) , Maria Grapini (S&D) , Norica Nicolai (ALDE) , Daciana Octavia Sârbu (S&D) , Sorin Moisă (S&D) , Victor Negrescu (S&D) , Emilian Pavel (S&D) , Claudia Țapardel (S&D) , Csaba Sógor (PPE)

 Subject:  Disparities in cancer indicators between Member States
 Answer in writing 

According to the report on the implementation of the Council Recommendation on cancer screening (May 2017), cancer is a major public health burden on the Member States, causing more than a million deaths every year. However, there are disparities among EU countries in the incidence of and mortality rates for cervical and breast cancer, in essence because of varying access to quality‐assured screening programmes for these types of cancer.

Romania does not have a national screening program for breast cancer. Bulgaria, Greece and Slovakia only have non-population-based programmes. Some of the longest running population-based cervical cancer screening programmes in the world are in EU countries (Finland and Sweden). Romania has the lowest values in terms of the indicators related to cancer survival (56% for cervical cancer and 63.9% for breast cancer), as well as high mortality and incidence ratios, due to poor health infrastructure, a lack of integrated medical services, difficulties in accessing new treatments and poor health education programmes.

What strategy is the Commission pursuing in order to reduce these substantial disparities between the Member States?

Could the Commission apply additional/specific recommendations, monitor the essential parameters and provide financial support for the health systems in countries with the lowest values in terms of cancer indicators?

Legal notice